» Articles » PMID: 36228339

A Review of Immune Checkpoint Blockade for the General Surgeon

Overview
Journal J Surg Res
Specialty General Surgery
Date 2022 Oct 13
PMID 36228339
Authors
Affiliations
Soon will be listed here.
Abstract

The immune system is a complex and interconnected system that has evolved to protect its host from foreign pathogens. CD8 T cells are a type of immune cell that can be directly lethal to tumor cells. However, their tumor killing capabilities can be inhibited by checkpoint molecules. During the last decade, the development of medications that block these checkpoint molecules has revolutionized treatment for some cancer types and indications for use continue to grow. As usage of immunotherapy increases, toxicities and adverse events unique to immunotherapy are becoming more prevalent. Here, we review the commonly targeted inhibitory molecules along with their food and drug administration-approved indications in various cancer therapeutic regimens, immunotherapy-related toxicities, and how this may impact surgical planning.

Citing Articles

ASO Author Reflections: Immune-Related Adverse Events During Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer May Influence Time to Adjuvant Radiation.

Myers S, Downs-Canner S Ann Surg Oncol. 2024; 31(8):5205-5206.

PMID: 38776008 DOI: 10.1245/s10434-024-15445-z.


Impact of Neoadjuvant Chemoimmunotherapy on Surgical Outcomes and Time to Radiation in Triple-Negative Breast Cancer.

Myers S, Sevilimedu V, Jones V, Abuhadra N, Montagna G, Plitas G Ann Surg Oncol. 2024; 31(8):5180-5188.

PMID: 38767803 DOI: 10.1245/s10434-024-15359-w.


Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab.

Lorig-Roach N, Harpell N, DuBois R Sci Rep. 2024; 14(1):742.

PMID: 38185735 PMC: 10772121. DOI: 10.1038/s41598-023-50262-6.


Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future.

Liu Y World J Gastroenterol. 2023; 29(34):5020-5037.

PMID: 37753366 PMC: 10518742. DOI: 10.3748/wjg.v29.i34.5020.

References
1.
Vinay D, Ryan E, Pawelec G, Talib W, Stagg J, Elkord E . Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015; 35 Suppl:S185-S198. DOI: 10.1016/j.semcancer.2015.03.004. View

2.
Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

3.
Weber J, Dummer R, de Pril V, Lebbe C, Hodi F . Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013; 119(9):1675-82. DOI: 10.1002/cncr.27969. View

4.
Wang D, Salem J, Cohen J, Chandra S, Menzer C, Ye F . Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018; 4(12):1721-1728. PMC: 6440712. DOI: 10.1001/jamaoncol.2018.3923. View

5.
Cappelli L, Gutierrez A, Bingham 3rd C, Shah A . Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care Res (Hoboken). 2016; 69(11):1751-1763. PMC: 5478477. DOI: 10.1002/acr.23177. View